home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9406b.zip
/
M9460352.TXT
< prev
next >
Wrap
Text File
|
1994-06-12
|
3KB
|
42 lines
Document 0352
DOCN M9460352
TI [Cancer of the kidney: changes in blood lymphocyte subsets induced by
treatment with interferon alpha-2b and interleukin-2r]
DT 9408
AU Raymond E; Boaziz C; Komarover H; Breau JL; Moliard M; Morere JF; Israel
L; Clinique d'oncologie medicale, Hopital Avicenne, Bobigny,; France.
SO Bull Cancer (Paris). 1993 Apr;80(4):299-309. Unique Identifier :
AIDSLINE MED/94227368
AB Twenty patients (6 females and 14 males), age range 36-70 years-old,
with metastatic renal cell carcinoma (MRCC), received interferon
alpha-2b (IFN-A) 10 x 10(6) units/day IM for 5 days followed by
continuous i.v. infusion of interleukin-2 (IL-2) 18 x 10(6) units/day
for 5 days. The median follow-up was 10 months. We observed four partial
responses (20%), 13 stable (65%) and three progressive diseases (15%).
The mean CD4/CD8 ratio, obtained before therapy in patients with MRCC,
was compared with CD4/CD8 ratio in 51 patients with different advanced
malignancy and in patients with no cancer. The CD4/CD8 ratio was higher
in patients with MRCC (2.55) than in other cancers (1.474) and than in
populations with no cancer (1.66 x chi 2 = 17,378). The surface
phenotypes of peripheral lymphocytes were analysed by cytofluorometry in
patients with MRCC during and after treatment with IFN-A and IL-2.
Immune modulatory effects of therapy immediately induced a decrease of
different sub-populations of lymphocytes except CD25+. Far from the
first course, a rise in lymphocyte count was observed. The proliferation
effect was as follows: CD4+, CD8+, CD4+ CD45RA- and CD16+ CD8- cells.
Far from the second and 3rd course, the sub-populations of lymphocytes
decreased, except the CD4+ and CD4- CD45RA+ cells. The CD4/CD8 ratio
increased progressively during treatment. Before each course, the
CD4/CD8 ratio of patients with response to treatment was higher than the
CD4/CD8 ratio of patients with no response. Results were non-significant
due to the small number of subjects with responses in this study.
DE Adult Aged B-Lymphocyte Subsets/*DRUG EFFECTS CD4-CD8 Ratio English
Abstract Female Human Interferon Alfa-2b/PHARMACOLOGY/*THERAPEUTIC
USE Interleukin-2/PHARMACOLOGY/*THERAPEUTIC USE Kidney
Neoplasms/BLOOD/*THERAPY Male Middle Age Neoplasm Metastasis
Treatment Outcome JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).